Payment overview · 2025
General Payments
$584.27
27 reported records · 12 companies
Healthcare provider profile · identity verified
Birendra Bhattarai, MD
Allopathic & Osteopathic Physicians|Internal Medicine · MOUNT DORA, FL · NPI 1851592802
Verified facts
What the public records show
CMS Open Payments records show Birendra Bhattarai, MD received $584.27 in general payments during 2025 across 27 reported records.
GlaxoSmithKline, LLC. accounted for 15.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Ozempic, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 181 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $89.54 | 15.3% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $89.11 | 15.2% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $72.01 | 12.3% | 4 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $67.60 | 11.6% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $60.94 | 10.4% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $49.05 | 8.4% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $32.70 | 5.6% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $31.84 | 5.5% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $26.42 | 4.5% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $24.80 | 4.2% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $23.99 | 4.1% | 1 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $16.27 | 2.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $584.27 | 27 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $70.05 | 3 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $67.60 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $54.95 | 3 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $37.88 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $35.98 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $34.59 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $34.59 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $32.70 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $31.84 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $31.84 | 2 | 2025 |
Source payment records
|
|||||
| VYNDAMAX Normalized: vyndamax |
Drug | PFIZER INC. | $29.57 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $26.42 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $24.80 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $23.99 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $23.06 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $22.04 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $19.48 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $19.48 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $19.48 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $19.24 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $19.06 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $16.79 | 1 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $16.27 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 58 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 67 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 83 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 68 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
58 | 17 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
67 | 19 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
68 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
67 | 19 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
83 | 27 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
181 | 57 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
41 | 41 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1356 | 414 |
| Amlodipine Besylate | Amlodipine Besylate | 978 | 283 |
| Levothyroxine Sodium | Levothyroxine Sodium | 896 | 253 |
| Lisinopril | Lisinopril | 770 | 238 |
| Losartan Potassium | Losartan Potassium | 624 | 189 |
| Omeprazole | Omeprazole | 617 | 186 |
| Metformin Hcl | Metformin Hcl | 591 | 176 |
| Simvastatin | Simvastatin | 545 | 157 |
| Metoprolol Tartrate | Metoprolol Tartrate | 521 | 169 |
| Methylprednisolone | Methylprednisolone | 506 | 269 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 462 | 109 |
| Alprazolam | Alprazolam | 450 | 105 |
| Gabapentin | Gabapentin | 441 | 145 |
| Hydrochlorothiazide | Hydrochlorothiazide | 409 | 111 |
| Pantoprazole Sodium | Pantoprazole Sodium | 406 | 124 |
| Azithromycin | Azithromycin | 398 | 217 |
| Furosemide | Furosemide | 396 | 133 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 395 | 124 |
| Tramadol Hcl | Tramadol Hcl | 365 | 86 |
| Clopidogrel | Clopidogrel Bisulfate | 336 | 96 |
| Tamsulosin Hcl | Tamsulosin Hcl | 334 | 105 |
| Potassium Chloride | Potassium Chloride | 333 | 112 |
| Sertraline Hcl | Sertraline Hcl | 320 | 87 |
| Metoprolol Succinate | Metoprolol Succinate | 313 | 91 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 306 | 97 |
| Meloxicam | Meloxicam | 291 | 74 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 282 | 168 |
| Trazodone Hcl | Trazodone Hcl | 282 | 78 |
| Glimepiride | Glimepiride | 268 | 77 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 237 | 77 |
| Carvedilol | Carvedilol | 218 | 65 |
| Pravastatin Sodium | Pravastatin Sodium | 207 | 57 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 202 | 42 |
| Allopurinol | Allopurinol | 200 | 54 |
| Duloxetine Hcl | Duloxetine Hcl | 193 | 51 |
| Montelukast Sodium | Montelukast Sodium | 182 | 52 |
| Eliquis | Apixaban | 181 | 57 |
| Celecoxib | Celecoxib | 176 | 59 |
| Metformin Hcl Er | Metformin Hcl | 159 | 48 |
| Warfarin Sodium | Warfarin Sodium | 157 | 32 |
| Fluticasone Propionate | Fluticasone Propionate | 153 | 65 |
| Escitalopram Oxalate | Escitalopram Oxalate | 151 | 42 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 142 | 97 |
| Clonazepam | Clonazepam | 141 | 30 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 138 | 37 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 138 | 43 |
| Baclofen | Baclofen | 137 | 52 |
| Alendronate Sodium | Alendronate Sodium | 127 | 40 |
| Atenolol | Atenolol | 125 | 37 |
| Pregabalin | Pregabalin | 120 | 36 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 119 | 73 |
| Citalopram Hbr | Citalopram Hydrobromide | 118 | 32 |
| Tizanidine Hcl | Tizanidine Hcl | 114 | 33 |
| Hydralazine Hcl | Hydralazine Hcl | 111 | 31 |
| Pioglitazone Hcl | Pioglitazone Hcl | 108 | 35 |
| Famotidine | Famotidine | 105 | 31 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 105 | 32 |
| Ropinirole Hcl | Ropinirole Hcl | 101 | 30 |
| Fluoxetine Hcl | Fluoxetine Hcl | 97 | 26 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 94 | 19 |
| Valsartan | Valsartan | 93 | 30 |
| Lorazepam | Lorazepam | 92 | 27 |
| Zolpidem Tartrate | Zolpidem Tartrate | 91 | 26 |
| Oxycodone Hcl | Oxycodone Hcl | 90 | 14 |
| Clonidine Hcl | Clonidine Hcl | 89 | 23 |
| Ezetimibe | Ezetimibe | 87 | 30 |
| Mirtazapine | Mirtazapine | 85 | 27 |
| Glipizide | Glipizide | 83 | 27 |
| Ozempic | Semaglutide | 83 | 27 |
| Spironolactone | Spironolactone | 81 | 25 |
| Buspirone Hcl | Buspirone Hcl | 78 | 28 |
| Meclizine Hcl | Meclizine Hcl | 78 | 31 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 76 | 47 |
| Amitriptyline Hcl | Amitriptyline Hcl | 74 | 17 |
| Quetiapine Fumarate | Quetiapine Fumarate | 74 | 21 |
| Temazepam | Temazepam | 74 | 15 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 73 | 33 |
| Prednisone | Prednisone | 73 | 40 |
| Synthroid | Levothyroxine Sodium | 73 | 22 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 72 | 37 |
| Topiramate | Topiramate | 72 | 23 |
| Donepezil Hcl | Donepezil Hcl | 71 | 22 |
| Dicyclomine Hcl | Dicyclomine Hcl | 68 | 19 |
| Ondansetron Hcl | Ondansetron Hcl | 68 | 29 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 68 | 17 |
| Jardiance | Empagliflozin | 67 | 19 |
| Ibuprofen | Ibuprofen | 66 | 26 |
| Lovastatin | Lovastatin | 65 | 19 |
| Sucralfate | Sucralfate | 65 | 26 |
| Diclofenac Sodium | Diclofenac Sodium | 64 | 26 |
| Finasteride | Finasteride | 63 | 22 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 62 | 26 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 62 | 21 |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 61 | 25 |
| Terazosin Hcl | Terazosin Hcl | 60 | 14 |
| Diazepam | Diazepam | 58 | 16 |
| Enalapril Maleate | Enalapril Maleate | 58 | 19 |
| Farxiga | Dapagliflozin Propanediol | 58 | 17 |
| Fluconazole | Fluconazole | 57 | 35 |
| Bupropion Xl | Bupropion Hcl | 56 | 16 |
| Estradiol | Estradiol | 56 | 17 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 56 | 26 |
| Nifedipine Er | Nifedipine | 56 | 13 |
| Memantine Hcl | Memantine Hcl | 55 | 13 |
| Fenofibrate | Fenofibrate | 54 | 16 |
| Oxybutynin Chloride | Oxybutynin Chloride | 54 | 16 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 53 | 16 |
| Januvia | Sitagliptin Phosphate | 51 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 47 | 14 |
| Glipizide Er | Glipizide | 46 | 15 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 46 | 14 |
| Xarelto | Rivaroxaban | 46 | 11 |
| Sildenafil Citrate | Sildenafil Citrate | 45 | 14 |
| Sotalol | Sotalol Hcl | 45 | 13 |
| Bumetanide | Bumetanide | 43 | 18 |
| Paxlovid | Nirmatrelvir/Ritonavir | 41 | 41 |
| Diltiazem Hcl | Diltiazem Hcl | 40 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 40 | suppressed |
| Jantoven | Warfarin Sodium | 40 | 13 |
| Amoxicillin | Amoxicillin | 39 | 17 |
| Nitroglycerin | Nitroglycerin | 39 | 23 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 38 | 14 |
| Gemfibrozil | Gemfibrozil | 38 | 16 |
| Metronidazole | Metronidazole | 38 | 26 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 37 | 18 |
| Paroxetine Hcl | Paroxetine Hcl | 37 | 14 |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 36 | 30 |
| Primidone | Primidone | 36 | 13 |
| Fenofibrate | Fenofibrate Nanocrystallized | 35 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 35 | 11 |
| Breo Ellipta | Fluticasone/Vilanterol | 34 | suppressed |
| Levemir Flexpen | Insulin Detemir | 34 | 12 |
| Nystatin | Nystatin | 34 | 21 |
| Ondansetron Odt | Ondansetron | 34 | 16 |
| Testosterone Cypionate | Testosterone Cypionate | 34 | 17 |
| Chlorthalidone | Chlorthalidone | 33 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 33 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 33 | 11 |
| Venlafaxine Hcl | Venlafaxine Hcl | 33 | suppressed |
| Lamotrigine | Lamotrigine | 32 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 32 | 13 |
| Benazepril Hcl | Benazepril Hcl | 31 | suppressed |
| Folic Acid | Folic Acid | 31 | 12 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 31 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 30 | suppressed |
| Methocarbamol | Methocarbamol | 29 | 13 |
| Levetiracetam | Levetiracetam | 28 | suppressed |
| Mupirocin | Mupirocin | 28 | 14 |
| Propranolol Hcl Er | Propranolol Hcl | 28 | suppressed |
| Acyclovir | Acyclovir | 27 | 13 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 27 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 27 | suppressed |
| Digoxin | Digoxin | 26 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 26 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 26 | 15 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 25 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 25 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 24 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 23 | suppressed |
| Ramipril | Ramipril | 23 | suppressed |
| Lactulose | Lactulose | 22 | 15 |
| Naproxen | Naproxen | 22 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 22 | 15 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 21 | suppressed |
| Irbesartan | Irbesartan | 21 | suppressed |
| Latanoprost | Latanoprost | 21 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 21 | suppressed |
| Phenobarbital | Phenobarbital | 21 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 20 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 20 | suppressed |
| Myrbetriq | Mirabegron | 20 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Risperidone | Risperidone | 20 | suppressed |
| Telmisartan | Telmisartan | 20 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 19 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 19 | suppressed |
| Cephalexin | Cephalexin | 19 | 15 |
| Lansoprazole | Lansoprazole | 19 | suppressed |
| Methimazole | Methimazole | 19 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 19 | suppressed |
| Cilostazol | Cilostazol | 17 | suppressed |
| Colchicine | Colchicine | 17 | suppressed |
| Ibu | Ibuprofen | 17 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Metolazone | Metolazone | 17 | suppressed |
| Novolog Flexpen | Insulin Aspart | 17 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 17 | 13 |
| Ventolin Hfa | Albuterol Sulfate | 17 | suppressed |
| Verapamil Er | Verapamil Hcl | 17 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 16 | suppressed |
| Lidocaine | Lidocaine | 16 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 16 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 15 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 15 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 15 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 15 | suppressed |
| Anastrozole | Anastrozole | 14 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 14 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 14 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 14 | suppressed |
| Repatha Syringe | Evolocumab | 14 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 13 | suppressed |
| Klor-Con M20 | Potassium Chloride | 13 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 13 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 13 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 13 | suppressed |
| Tadalafil | Tadalafil | 13 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Calcitriol | Calcitriol | 12 | suppressed |
| Carbamazepine Er | Carbamazepine | 12 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 12 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 12 | suppressed |
| Paxlovid (Eua) | Nirmatrelvir/Ritonavir | 12 | 12 |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 12 | suppressed |
| Ranolazine Er | Ranolazine | 12 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Aripiprazole | Aripiprazole | 11 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 11 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 11 | suppressed |
| Carisoprodol | Carisoprodol | 11 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 11 | suppressed |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 11 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 11 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 11 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 11 | suppressed |
| Novolog Mix 70-30 | Insulin Aspart Prot/Insuln Asp | 11 | suppressed |
| Olanzapine | Olanzapine | 11 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 11 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $584.27 · 27 records | GlaxoSmithKline, LLC. | ABRYSVO, AIRSUPRA, AREXVY, BREZTRI, CAPVAXIVE, COMIRNATY, Cologuard Collection Kit, FARXIGA, GEMTESA, JARDIANCE, LifeVest, MOUNJARO, OTEZLA, Ozempic, PREVNAR 20, REPATHA, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, VOQUEZNA, VYNDAMAX, Wegovy | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error